Rezolute Receives Breakthrough Therapy Designation from FDA for Ersodetug in the Treatment ...
Breakthrough Therapy Designation granted based on key positive data from the Phase 2b (RIZE) study and current unmet medical need in congenital ...
Rezolute receives BTD from FDA for ersodetug in treatment of hypoglycemia
Rezolute (RZLT) announced that the U.S. Food and Drug Administration, FDA, has granted Breakthrough Therapy Designation, BTD, to ersodetug, ...
Medical News Today4 年
Low blood sugar (hypoglycemia) symptoms
People with diabetes who experience hypoglycemia symptoms while on a treatment plan should talk to their doctor, as their medicine or diet may need changing. People can help prevent future ...
Medscape9 年
Evidence-informed Clinical Practice Recommendations for Treatment of Type 1 Diabetes ...
Glycemic and hypoglycemia treatment targets should be individualized and reassessed every 3–6 months. If targets are not met, one diabetes technology—continuous subcutaneous insulin infusion ...
Nasdaq1 个月
FDA Grants Orphan Drug Designation to Rezolute’s Ersodetug (RZ358) for the Treatment of ...
today announced the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to ersodetug for the treatment of hypoglycemia due to tumor HI. "FDA's granting of Orphan Drug ...
Stockhouse1 个月
FDA Grants Orphan Drug Designation to Rezolute's Ersodetug (RZ358) for the Treatment of ...
today announced the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to ersodetug for the treatment of hypoglycemia due to tumor HI. "FDA's granting of Orphan Drug ...